CFS_CARE- Care Concept for Patients with Myalgic Encephalo-myelitis/Chronic Fatigue Syndrome/ (ME/CFS)

CFS_CARE- Care Concept for Patients with Myalgic Encephalo-myelitis/Chronic Fatigue Syndrome/ (ME/CFS) - CFS_Care

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00026960

Enrollment

240

Registered

2021-11-04

Start date

2022-01-10

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G93.3

Interventions

Group 1: Intervention arm - Diagnostics Therapy recommendation by specialized physicians of Charité - Rehabilitation program with inpatient treatment - outpatient further care via the Charité An ove

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: CFS within 5 years of onset, Bell score 30-70, Canadian consensus criteria met, 18-65 years, ability to consent, BKK insured.

Exclusion criteria

Exclusion criteria: Other conditions associated with chronic fatigue e.g. fatigue after cancer

Design outcomes

Primary

Measure	Time frame
Physical dimension of the SF36 measured 12 months after study inclusion.	—

Secondary

Measure	Time frame
- Bell disability scale (at 0, 3, 6, 9, 12 months) - Chalder fatigue scale (at 0, 3, 6, 9, 12 months) - CCC criteria (at 0, 3, 6, 9, 12 months) - COMPASS31 scale (at 0, 3, 6, 9, 12 months in the intervention group, at 6 and 12 months in the control group) - Hand strength month 0 and 12 - Schellong test month 0 and 12 - Step counts measured with pedometer at 0, 6 and 12 months - IPAQ questionnaire after 0, 3, 6 and 12 months - Sick days in the period 3 months to 12 months after study inclusion - Blood parameters (CK, LDH, NT-pro BNP, albumin, ferritin, transferrin saturation, calcium, phosphate,) month 0 and 12 - PHQ9 Month 0 and 12 - ESS Month 0 and 12 Translated with www.DeepL.com/Translator (free version)	—

Measure

Time frame

- Bell disability scale (at 0, 3, 6, 9, 12 months) - Chalder fatigue scale (at 0, 3, 6, 9, 12 months) - CCC criteria (at 0, 3, 6, 9, 12 months) - COMPASS31 scale (at 0, 3, 6, 9, 12 months in the intervention group, at 6 and 12 months in the control group) - Hand strength month 0 and 12 - Schellong test month 0 and 12 - Step counts measured with pedometer at 0, 6 and 12 months - IPAQ questionnaire after 0, 3, 6 and 12 months - Sick days in the period 3 months to 12 months after study inclusion - Blood parameters (CK, LDH, NT-pro BNP, albumin, ferritin, transferrin saturation, calcium, phosphate,) month 0 and 12 - PHQ9 Month 0 and 12 - ESS Month 0 and 12 Translated with www.DeepL.com/Translator (free version)

—

Countries

Germany

Contacts

Public ContactCarmen Scheibenbogen

Charité - Institut für Medizinische Immunologie

carmen.scheibenbogen@charite.de+4930 450 524 103

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026